These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7064804)

  • 41. Use of vasodilator drugs in congestive heart failure.
    Med Lett Drugs Ther; 1978 Oct; 20(20):89-91. PubMed ID: 703684
    [No Abstract]   [Full Text] [Related]  

  • 42. Afterload reduction in the treatment of cardiac failure.
    Mason DT
    Schweiz Med Wochenschr; 1978 Nov; 108(44):1695-703. PubMed ID: 102028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance.
    Massie BM; Kramer B; Haughom F
    Circulation; 1981 Dec; 64(6):1218-26. PubMed ID: 6794935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
    Massie B; Chatterjee K; Werner J; Greenberg B; Hart R; Parmley WW
    Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement in exercise haemodynamics by isosorbide dinitrate in patients with severe congestive cardiac failure secondary to ischaemic heart disease.
    Stephens J; Camm J; Spurrell R
    Br Heart J; 1978 Aug; 40(8):832-7. PubMed ID: 687484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of sublingual isosorbide dinitrate on hemodynamics in coronary patients with and without congestive heart failure (author's transl)].
    Wolf R; Beck OA; Habel F; Hochrein H
    Z Kardiol; 1977 Aug; 66(8):459-64. PubMed ID: 899150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Use of peripheral vasodilators with different mechanisms of action in treating heart failure patients].
    Novikov SV; Mareev VIu; Elizarova NA; Naumov VG; Sazonova LN
    Ter Arkh; 1987; 59(9):126-30. PubMed ID: 3424177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure.
    Franciosa JA; Cohn JN
    Am J Med; 1978 Jul; 65(1):126-33. PubMed ID: 685986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current indications for vasodilator therapy for left ventricular failure.
    Franciosa JA
    Compr Ther; 1985 Mar; 11(3):39-46. PubMed ID: 2983926
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of the effects of dopamine, hydralazine, and isosorbide dinitrate on myocardial hemodynamics in patients with refractory heart failure.
    Biddle TL; Moses HW
    J Clin Pharmacol; 1981; 21(8-9):343-50. PubMed ID: 7276228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.
    Steimle AE; Stevenson LW; Chelimsky-Fallick C; Fonarow GC; Hamilton MA; Moriguchi JD; Kartashov A; Tillisch JH
    Circulation; 1997 Aug; 96(4):1165-72. PubMed ID: 9286945
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Modern vasodilator medication in refractory cardiac insufficiency].
    Stanciu L; Branea I; Riviş I; Radivoievici A; Mancaş S; Păunescu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(2):129-34. PubMed ID: 6139858
    [No Abstract]   [Full Text] [Related]  

  • 53. Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
    Packer M
    Chest; 1980 Jan; 77(1):7-9. PubMed ID: 7351152
    [No Abstract]   [Full Text] [Related]  

  • 54. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN
    Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators.
    Rubin SA; Chatterjee K; Parmley WW
    Circulation; 1980 Mar; 61(3):543-8. PubMed ID: 7353245
    [No Abstract]   [Full Text] [Related]  

  • 57. [Vasodilator therapy in cardiac failure].
    Akatsuka N
    Nihon Rinsho; 1993 May; 51(5):1276-80. PubMed ID: 8101237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure.
    Rude RE; Turi Z; Brown EJ; Lorell BH; Colucci WS; Mudge GH; Taylor CR; Grossman W
    Circulation; 1981 Jul; 64(1):139-45. PubMed ID: 7237712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure.
    Wilson JR; Untereker W; Hirshfeld J
    Am J Cardiol; 1981 Nov; 48(5):934-8. PubMed ID: 7304441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vasodilator therapy for chronic left ventricular failure.
    Kovick RB; Tillisch JH; Berens SC; Bramowitz AD; Shine KI
    Circulation; 1976 Feb; 53(2):322-8. PubMed ID: 812614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.